Methylxanthines: Potential Therapeutic Agents for Glioblastoma

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Pérez, Daniel, Reyes-Vidal, Iannel, Chávez-Cortez, Elda Georgina, Sotelo, Julio, Magaña-Maldonado, Roxana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Concept Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789489/
https://www.ncbi.nlm.nih.gov/pubmed/31500285
http://dx.doi.org/10.3390/ph12030130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789489/
https://www.ncbi.nlm.nih.gov/pubmed/31500285
http://dx.doi.org/10.3390/ph12030130

Ejemplares similares